Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly

doi:10.1016/S0140-6736(10)62175-7

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles
, John Francis Seymour
, Fritz Offner
, Armando López-Guillermo
, David Belada
, Luc Xerri
, Pierre Feugier
, Réda Bouabdallah
, John Vincent Catalano
, Pauline Brice
, Dolores Caballero
, Corinne Haioun
, Lars Moller Pedersen
, Alain Delmer
, David Simpson
, Sirpa Leppa
, Pierre Soubeyran
, Anton Hagenbeek
, Olivier Casasnovas
, Tanin Intragumtornchai

Christophe Fermé, Maria Gomes da Silva, Catherine Sebban, Andrew Lister, Jane A Estell, Gustavo Milone, Anne Sonet, Myriam Mendila, Bertrand Coiffier, Hervé Tilly

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

Patients with follicular lymphoma can have long survival times, but disease progression typically occurs 3-5 years after initial treatment. We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen.

Originalsprog	Engelsk
Tidsskrift	The Lancet
Vol/bind	377
Udgave nummer	9759
Sider (fra-til)	42-51
Antal sider	10
ISSN	0140-6736
DOI	https://doi.org/10.1016/S0140-6736(10)62175-7
Status	Udgivet - 2011

Dokumenter og links

10.1016/S0140-6736(10)62175-7

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

Salles, G., Seymour, J. F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., Caballero, D., Haioun, C., Pedersen, L. M., Delmer, A., Simpson, D., Leppa, S., Soubeyran, P., Hagenbeek, A., Casasnovas, O., ... Tilly, H. (2011). Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. The Lancet, 377(9759), 42-51. https://doi.org/10.1016/S0140-6736(10)62175-7

@article{f4d281fa53914355958cab072a545cd3,

title = "Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial",

abstract = "Patients with follicular lymphoma can have long survival times, but disease progression typically occurs 3-5 years after initial treatment. We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen.",

keywords = "Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents, Disease Progression, Female, Humans, Immunologic Factors, Lymphoma, Follicular, Male, Middle Aged, Remission Induction, Tumor Burden, Young Adult",

author = "Gilles Salles and Seymour, \{John Francis\} and Fritz Offner and Armando L{\'o}pez-Guillermo and David Belada and Luc Xerri and Pierre Feugier and R{\'e}da Bouabdallah and Catalano, \{John Vincent\} and Pauline Brice and Dolores Caballero and Corinne Haioun and Pedersen, \{Lars Moller\} and Alain Delmer and David Simpson and Sirpa Leppa and Pierre Soubeyran and Anton Hagenbeek and Olivier Casasnovas and Tanin Intragumtornchai and Christophe Ferm{\'e} and \{da Silva\}, \{Maria Gomes\} and Catherine Sebban and Andrew Lister and Estell, \{Jane A\} and Gustavo Milone and Anne Sonet and Myriam Mendila and Bertrand Coiffier and Herv{\'e} Tilly",

year = "2011",

doi = "10.1016/S0140-6736(10)62175-7",

language = "English",

volume = "377",

pages = "42--51",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9759",

}

Salles, G, Seymour, JF, Offner, F, López-Guillermo, A, Belada, D, Xerri, L, Feugier, P, Bouabdallah, R, Catalano, JV, Brice, P, Caballero, D, Haioun, C, Pedersen, LM, Delmer, A, Simpson, D, Leppa, S, Soubeyran, P, Hagenbeek, A, Casasnovas, O, Intragumtornchai, T, Fermé, C, da Silva, MG, Sebban, C, Lister, A, Estell, JA, Milone, G, Sonet, A, Mendila, M, Coiffier, B & Tilly, H 2011, 'Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial', The Lancet, bind 377, nr. 9759, s. 42-51. https://doi.org/10.1016/S0140-6736(10)62175-7

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. / Salles, Gilles; Seymour, John Francis; Offner, Fritz et al.
I: The Lancet, Bind 377, Nr. 9759, 2011, s. 42-51.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

AU - Salles, Gilles

AU - Seymour, John Francis

AU - Offner, Fritz

AU - López-Guillermo, Armando

AU - Belada, David

AU - Xerri, Luc

AU - Feugier, Pierre

AU - Bouabdallah, Réda

AU - Catalano, John Vincent

AU - Brice, Pauline

AU - Caballero, Dolores

AU - Haioun, Corinne

AU - Pedersen, Lars Moller

AU - Delmer, Alain

AU - Simpson, David

AU - Leppa, Sirpa

AU - Soubeyran, Pierre

AU - Hagenbeek, Anton

AU - Casasnovas, Olivier

AU - Intragumtornchai, Tanin

AU - Fermé, Christophe

AU - da Silva, Maria Gomes

AU - Sebban, Catherine

AU - Lister, Andrew

AU - Estell, Jane A

AU - Milone, Gustavo

AU - Sonet, Anne

AU - Mendila, Myriam

AU - Coiffier, Bertrand

AU - Tilly, Hervé

PY - 2011

Y1 - 2011

N2 - Patients with follicular lymphoma can have long survival times, but disease progression typically occurs 3-5 years after initial treatment. We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen.

AB - Patients with follicular lymphoma can have long survival times, but disease progression typically occurs 3-5 years after initial treatment. We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicular lymphoma receiving a rituximab plus chemotherapy regimen.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antibodies, Monoclonal, Murine-Derived

KW - Antineoplastic Agents

KW - Disease Progression

KW - Female

KW - Humans

KW - Immunologic Factors

KW - Lymphoma, Follicular

KW - Male

KW - Middle Aged

KW - Remission Induction

KW - Tumor Burden

KW - Young Adult

U2 - 10.1016/S0140-6736(10)62175-7

DO - 10.1016/S0140-6736(10)62175-7

M3 - Journal article

C2 - 21176949

SN - 0140-6736

VL - 377

SP - 42

EP - 51

JO - The Lancet

JF - The Lancet

IS - 9759

ER -

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Abstract

Dokumenter og links

SDU link

Fingeraftryk

Citationsformater